World Library  
Flag as Inappropriate
Email this Article

Diffuse myelinoclastic sclerosis

Article Id: WHEBN0022994605
Reproduction Date:

Title: Diffuse myelinoclastic sclerosis  
Author: World Heritage Encyclopedia
Language: English
Subject: List of MeSH codes (C10), Multiple sclerosis, Acute disseminated encephalomyelitis, Laquinimod, Infantile progressive bulbar palsy
Collection: Autoimmune Diseases, Demyelinating Diseases of Cns
Publisher: World Heritage Encyclopedia

Diffuse myelinoclastic sclerosis

Diffuse myelinoclastic sclerosis
Classification and external resources
ICD-10 G37.0
ICD-9 341.1
OMIM 272100
DiseasesDB 11849
eMedicine neuro/92
MeSH D002549

Diffuse myelinoclastic sclerosis, sometimes referred to as "Schilder's disease", is a very infrequent neurodegenerative disease that presents clinically as pseudotumoural demyelinating lesions, that make its diagnosis difficult. It usually begins in childhood, affecting children between 5 and 14 years old,[1][2] but cases in adults are possible.[3]

This disease is considered one of the borderline forms of multiple sclerosis because some authors consider them different diseases and others MS variants. Other diseases in this group are neuromyelitis optica (NMO), Balo concentric sclerosis and Marburg multiple sclerosis.[4]


  • Symptoms 1
  • Neuropathological examination 2
  • Diagnostic 3
  • Prognosis and clinical course 4
  • Treatments 5
  • History 6
  • References 7
  • External links 8


Symptoms are similar to those in multiple sclerosis and may include dementia, aphasia, seizures, personality changes, poor attention, tremors, balance instability, incontinence, muscle weakness, headache, vomiting, and vision and speech impairment.[5]

Neuropathological examination

The typical demyelinating plaques in Schilder's sclerosis are usually found bilaterally in the semioval center; both hemispheres are almost completely occupied by large, well defined lesions. Although plaques of this kind are largely prevalent in Schilder's sclerosis, smaller lesions can also be observed.


The Poser criteria for diagnosis are:[6]

  • One or two roughly symmetrical large plaques. Plaques are greater than 2 cm diameter.
  • No other lesions are present and there are no abnormalities of the peripheral nervous system.
  • Results of adrenal function studies and serum very long chain fatty acids are normal.
  • Pathological analysis is consistent with subacute or chronic myelinoclastic diffuse sclerosis.

Prognosis and clinical course

The prognosis of this disease is very variable and can take three different courses: a monophasic, not remitting; [2] ,[7] remitting;[8] [9] [10] and finally, progressive, with increase in deficits.[11]


Management Corticosteroids may be effective in some patients. Additional treatment options are beta-interferon or immunosuppressive therapy. Otherwise management is supportive and includes physiotherapy, occupational therapy and nutritional support in the later stages as patients lose their ability to eat.


It was first described by Paul Ferdinand Schilder in 1912,[12][13] and for nearly one hundred years the term Schilder disease was used to describe it, but the same name was also used for some other white matter pathologies described by him.[14] In 1986 Poser tried to restrict the use of Schilder's disease name to the disease described here, but this name has remained still ambiguous.


  1. ^ Garrido C, Levy-Gomes A, Teixeira J, Temudo T (2004). "[Schilder's disease: two new cases and a review of the literature]". Revista de neurologia (in Spanish) 39 (8): 734–8.  
  2. ^ a b Afifi AK, Bell WE, Menezes AH, Moore SA (1994). "Myelinoclastic diffuse sclerosis (Schilder's disease): report of a case and review of the literature". J. Child Neurol. 9 (4): 398–403.  
  3. ^ Bacigaluppi, S; Polonara, G; Zavanone, ML; Campanella, R; Branca, V; Gaini, SM; Tredici, G; Costa, A (2009). "Schilder's disease: non-invasive diagnosis? :A case report and review.". Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 30 (5): 421–30.  
  4. ^ Fontaine B (2001). "[Borderline forms of multiple sclerosis]". Rev. Neurol. (Paris) (in French) 157 (8-9 Pt 2): 929–34.  
  5. ^ NINDS Schilder's Disease Information Page
  6. ^ Poser CM, Goutières F, Carpentier MA, Aicardi J (1986). "Schilder's myelinoclastic diffuse sclerosis". Pediatrics 77 (1): 107–12.  
  7. ^ Pretorius ML, Loock DB, Ravenscroft A, Schoeman JF (1998). "Demyelinating disease of Schilder type in three young South African children: dramatic response to corticosteroids". J. Child Neurol. 13 (5): 197–201.  
  8. ^ de Lacour A, Guisado F, Zambrano A, Argente J, Acosta J, Ramos C (1998). "[Pseudotumor forms of demyelinating diseases. Report of three cases and review of the literature]". Revista de neurologia (in Spanish; Castilian) 27 (160): 966–70.  
  9. ^ Leuzzi V, Lyon G, Cilio MR, Pedespan JM, Fontan D, Chateil JF, Vital A (1999). "Childhood demyelinating diseases with a prolonged remitting course and their relation to Schilder's disease: report of two cases". J. Neurol. Neurosurg. Psychiatr. 66 (3): 407–8.  
  10. ^ Brunot E, Marcus JC (1999). "Multiple sclerosis presenting as a single mass lesion". Pediatr. Neurol. 20 (5): 383–6.  
  11. ^ Garell PC, Menezes AH, Baumbach G, Moore SA, Nelson G, Mathews K, Afifi AK (1998). "Presentation, management and follow-up of Schilder's disease". Pediatric neurosurgery 29 (2): 86–91.  
  12. ^ synd/1554 at Who Named It?
  13. ^ P. F. Schilder, Zur Kenntnis der sogenannten diffusen Sklerose (über Encephalitis periaxialis diffusa). Zeitschrift für die gesamte Neurologie und Psychiatrie, 1912, 10 Orig.: 1-60.
  14. ^ Martin JJ, Guazzi GC (1991). "Schilder's diffuse sclerosis". Dev. Neurosci. 13 (4-5): 267–73.  

External links

  • WebMD - Schilder's Disease
  • schilders at NINDS

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.